Story perspectives

Bristol Myers Unveils $2.5B Restructuring Plan Amidst Competition

9/21/2025

36 3

Summary

Story summary

Bristol Myers (BMY) is restructuring with a $2.5 billion program to boost growth amid generic competition, targeting $2 billion in annual savings by 2027.
The plan focuses on streamlining R&D, manufacturing, and commercial operations.
BMY's projected operating expenses for 2025 are $16.5 billion, up from $16.2 billion due to new investments.
BMY shares have dropped 16.5% this year, while the industry has grown by 4.9%.
BMY's price/earnings ratio stands at 7.36X, below industry averages.

1 of 1

Story summary

Bristol Myers (BMY) is restructuring with a $2.5 billion program to boost growth amid generic competition, targeting $2 billion in annual savings by 2027.
The plan focuses on streamlining R&D, manufacturing, and commercial operations.
BMY's projected operating expenses for 2025 are $16.5 billion, up from $16.2 billion due to new investments.
BMY shares have dropped 16.5% this year, while the industry has grown by 4.9%.
BMY's price/earnings ratio stands at 7.36X, below industry averages.